STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] Cardlytics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Cardlytics, Inc. (CDLX) Form 144 notice shows an insider intends to sell 8,493 shares of common stock, with an aggregate market value of $19,286.75, on or about 10/02/2025 through Fidelity Brokerage Services LLC on NASDAQ. The shares were acquired on 10/01/2025 by restricted stock vesting as compensation. The filer also reported two prior sales in the past three months: 7,324 shares sold on 07/02/2025 for $13,055.76 and 26,048 shares sold on 08/15/2025 for $31,695.21. The filer certifies no undisclosed material adverse information is known.

Positive
  • 8,493 shares acquired by restricted stock vesting, indicating compensation rather than open-market purchase
  • Sale will be executed through Fidelity Brokerage Services LLC on the NASDAQ, a regulated venue
Negative
  • Insider proposes sale of 8,493 shares with aggregate market value $19,286.75, increasing insider supply
  • Two prior sales in last three months totaling 33,372 shares were reported, potentially increasing sell-side pressure

Insights

Insider plans to sell recently vested 8,493 shares on 10/02/2025.

The filing states the 8,493 shares were acquired on 10/01/2025 through restricted stock vesting and are to be sold for an aggregate market value of $19,286.75 via Fidelity Brokerage Services LLC on NASDAQ.

The Form 144 also discloses two earlier sales by the same person in the past three months: 7,324 shares on 07/02/2025 for $13,055.76 and 26,048 shares on 08/15/2025 for $31,695.21, which are reported in the filing.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for Cardlytics (CDLX) disclose?

It discloses an intended sale of 8,493 common shares valued at $19,286.75 with an approximate sale date of 10/02/2025 via Fidelity Brokerage Services LLC on NASDAQ.

How were the 8,493 Cardlytics shares acquired?

The filing states the shares were acquired on 10/01/2025 through restricted stock vesting and the payment nature is listed as compensation.

Has the filer sold other Cardlytics shares recently?

Yes. The filer sold 7,324 shares on 07/02/2025 for $13,055.76 and 26,048 shares on 08/15/2025 for $31,695.21.

Who is the broker and where will the sale occur?

The broker is Fidelity Brokerage Services LLC and the sale is planned on the NASDAQ exchange.

Does the filer assert any undisclosed material information?

By signing the notice, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Cardlytics

NASDAQ:CDLX

CDLX Rankings

CDLX Latest News

CDLX Latest SEC Filings

CDLX Stock Data

66.49M
52.46M
2.95%
45.79%
14.27%
Advertising Agencies
Services-computer Programming, Data Processing, Etc.
Link
United States
ATLANTA